Eli Lilly and Company (LLY) vs Novartis AG (NVS)
Eli Lilly and Company and Novartis AG are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.11T against $264.3B — 4.2× the size. Novartis AG trades at the lower P/E: 21.8× against 39.7×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 2.73%. Eli Lilly and Company has the higher net margin (33.5% vs 22.5%) and the higher return on invested capital (26.3% vs 13.1%). Both pay a dividend; Novartis AG yields more (3.69% vs 0.72%). Across the 23 metrics below, Novartis AG leads on 12 and Eli Lilly and Company on 11.
Valuation
Profitability
| Metric | LLY | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 83.40% | 74.74% | 72.77% |
| Operating margin | 42.22% | 30.17% | 18.90% |
| Net margin | 33.53% | 22.50% | 8.27% |
| Free cash flow margin | 22.83% | 26.77% | 17.25% |
| Return on equity | 102.29% | 30.37% | 6.97% |
| Return on assets | 21.97% | 11.27% | 2.76% |
| Return on invested capital | 26.33% | 13.14% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack